Nectar Lifesciences Limited has extended the timeline for completing the slump sale of its empty hard gelatin capsule business to on or before December 31, 2026. The company announced the extension in a disclosure submitted to the National Stock Exchange of India Limited and BSE Limited on July 23, 2026. The revised deadline reflects a mutual agreement between Nectar Lifesciences and the purchaser, Capnest Health Care Private Limited, to finalize the transaction within the new timeframe.

The slump sale involves the transfer of the company’s empty hard gelatin capsule business as a going concern. This transaction was initially disclosed on December 20, 2025, via letter reference NLL/CS/2025-WFH, with subsequent updates provided on April 28, 2026, under reference NLL/CS/2026-675. The current disclosure, referenced as NLL/CS/2026-697, confirms that while the completion date has shifted, all other relevant terms and disclosures pertaining to the slump sale remain unchanged from the initial announcement.

Transaction Timeline

The company cited Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, for making this disclosure. Sanjaymohan Singh Rawat, Company Secretary & Compliance Officer of Nectar Lifesciences Limited, signed the communication. The filing notes that all other relevant disclosures required under the LODR Regulations, as detailed in Annexure 1 to the initial December 2025 letter, continue to hold valid without modification.

What This Means for Shareholders

The extension of the slump sale completion date indicates that the divestment of the empty hard gelatin capsule business will take longer than previously anticipated. For investors, this means the financial impact of the transaction — including any potential proceeds or restructuring benefits — will be realized no earlier than the end of 2026. The mutual agreement suggests that both parties are committed to the deal but require additional time to satisfy regulatory, operational, or legal prerequisites for closing. No changes were reported to the core terms of the sale, implying that the strategic rationale for the divestment remains intact despite the delay.

Nectar Lifesciences Limited has published its audited financial results for the quarter and financial year ended March 31, 2026. The company reported a consolidated net loss of ₹29,288.48 lakh for the year ended March 31, 2026, compared to a net loss of ₹6,792.42 lakh in the previous year. The standalone net loss for the period stood at ₹6,791.80 lakh. The results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on May 30, 2026.

The financial statements were published in newspapers on June 1, 2026, complying with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Board confirmed that the audit reports do not have any modified opinion. Previous year figures have been regrouped and reclassified where necessary to ensure comparability.

Financial Performance

The table below summarizes the key financial metrics for the standalone and consolidated entities for the quarter and year ended March 31, 2026:

The company reported a total comprehensive loss of ₹6,783.88 lakh on a standalone basis and ₹29,280.56 lakh on a consolidated basis for the financial year. The paid-up share capital stood at ₹1,942.61 lakh with a face value of ₹1 per share.

Earnings Per Share

The basic and diluted earnings per share (EPS) for continuing and discontinued operations reflected the losses incurred during the period. On a consolidated basis, the basic EPS for continuing operations was (₹2.85), while for discontinued operations it was (₹11.72). The total basic EPS for continuing and discontinued operations combined was (₹14.58).